NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod
This article was originally published in The Pink Sheet Daily
Executive Summary
French firm plans to build U.S. sales force to market osteoarthritis drug and complementary products it will acquire or license.
You may also be interested in...
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.
NicOx Data Positive, But Is it Enough?
NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.